enzastaurin has been researched along with Local Neoplasm Recurrence in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butman, JA; Fine, HA; Fraum, TJ; Iwamoto, FM; Kreisl, TN; Li, A; Moustakas, A; Odia, Y; Salgado, CA; Sul, J | 1 |
| Albert, PS; Duic, P; Fine, HA; Kim, L; Kotliarova, S; Kreisl, TN; Moore, K; Musib, L; Thornton, D; Walling, J | 1 |
| Berglund, A; Byström, P; Cleverly, A; Darstein, C; Frödin, JE; Gawande, S; Glimelius, B; Jakobsen, A; Lahn, M; Liu, Y; Musib, L; Pfeiffer, P; Qvortrup, C; Spindler, KL | 1 |
| Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W | 1 |
| Albert, PS; Butman, JA; Fine, HA; Kim, L; Kotliarova, S; Kreisl, TN; Musib, L; Thornton, D | 1 |
| Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J | 1 |
| Benbrook, DM; Darcy, KM; De Geest, K; Godwin, AK; Hanjani, P; Hurteau, JA; Mannel, RS; Michelin, DP; Sill, MW; Usha, L | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
8 trial(s) available for enzastaurin and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Follow-Up Studies; Glioma; Glycogen Synthase Kinase 3; Humans; Indoles; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate | 2016 |
A phase I trial of enzastaurin in patients with recurrent gliomas.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Glioma; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Long QT Syndrome; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Phosphoproteins; Protein Kinase C; Protein Kinase C beta; Survival Analysis; Thrombocytopenia | 2009 |
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Protein Kinase C; Protein Kinase C beta; Tissue Distribution | 2010 |
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Glioblastoma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local | 2010 |
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Indoles; Kaplan-Meier Estimate; Neoplasm Recurrence, Local | 2010 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Mexico; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placebo Effect; Proportional Hazards Models; Risk Assessment; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2010 |
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Class I Phosphatidylinositol 3-Kinases; Female; Genes, p53; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Vascular Endothelial Growth Factor A | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |